Business
Middle Man Running on Mountain Road
(Getty Images)
footrace

Hoka running shoes have been right on Ugg’s heels, but growth is slowing and the future looks uncertain

Deckers’ stock dropped after not providing guidance for its coming fiscal year as Hoka sales slow.

Tom Jones

You may have noticed that almost everyone you know is into running now. People pad along sidewalks like never before, share Strava highlights to their stories like nobody’s business, and even use running to find love.

Naturally, that vibe shift has played into the hands (or feet) of one of America’s biggest footwear companies.

Positive splits

Ugg, the brand best known for its sheepskin, fleece-lined boots, has long occupied the top shelf in the Deckers shoe closet, posting almost $20 billion in revenues over the last 10 years. However, ultra-cushioned running sneaker brand Hoka has sprinted in recent years to almost catch up with Ugg’s bumper sales figures, pulling in $2.23 billion for Deckers Outdoor in the last fiscal year.

Hoka and Ugg sales chart
Sherwood News

Recently, though, the lightning pace Hoka had set is slowing, with annual sales growth dropping from 58% to 28% to 23% in the last three fiscal years. And looking ahead, the trajectory of Deckers’ all-important ascendent brand is uncertain, with the company declining to provide any financial guidance for the coming year in its results, blaming “macroeconomic uncertainty related to evolving global trade policies.” Traders have been dumping the stock in response, which dropped as much as 22% in early trading on Friday.

Alongside Swiss giant On, buzz has built around Hoka in the running community for years now, with mainstream publications now putting out pieces every few months about how the two have come to challenge established names like Nike and Adidas.

Still, with shares down more than 50% so far this year, investors have lost faith in the journey recently.

More Business

See all Business
The Sphere In Las Vegas

Washington D.C. looks set to get America’s second Sphere

Revenue for the Las Vegas version of the big orb has soared, but the sphere is still a money pit.

business

Ford reportedly in talks to buy hybrid vehicle batteries from Chinese auto giant BYD

Detroit’s Ford and China’s BYD are said to be in ongoing talks to partner on an agreement that would see Ford buy hybrid vehicle batteries from BYD, according to reporting from The Wall Street Journal.

The report comes just days after President Trump toured a Ford factory in Michigan and implied openness to Chinese automakers coming to the US.

“If they want to come in and build a plant... that’s great, I love that,” Trump said on January 13. “Let China come in, let Japan come in.”

Last week, China’s Geely Automobile Holdings said it expects to make an announcement about expanding into the US within the next three years. Chinese carmakers currently face huge tariffs and software restrictions, effectively barring their vehicles from the US.

Ford has doubled down on hybrid vehicles amid high EV costs and the end of federal EV tax credits. The automaker is currently building a battery plant in Michigan where it plans to use tech from Chinese battery maker CATL.

“If they want to come in and build a plant... that’s great, I love that,” Trump said on January 13. “Let China come in, let Japan come in.”

Last week, China’s Geely Automobile Holdings said it expects to make an announcement about expanding into the US within the next three years. Chinese carmakers currently face huge tariffs and software restrictions, effectively barring their vehicles from the US.

Ford has doubled down on hybrid vehicles amid high EV costs and the end of federal EV tax credits. The automaker is currently building a battery plant in Michigan where it plans to use tech from Chinese battery maker CATL.

Still life of Ozempic and Wegovy with weight scale.

Lawsuit alleges Lilly, Novo locked up telehealth to kill compounded GLP-1s

Novo Nordisk CEO Mike Doustdar estimated that around 1.5 million US patients are using compounded versions of the company’s drugs.

Handshake

Big Pharma enters 2026 with an appetite for deals

At the JPMorgan Healthcare Conference, biotechs and Big Pharma signaled they’re primed for M&A this year, after a big year for deals in 2025.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.